Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance

Linlin Shi,Jianyong Sheng,Guozhong Chen,Peng Zhu,Changping Shi,Bei Li,Chaiwoo Park,Jingyi Wang,Bixiang Zhang,Zhi Liu,Xiangliang Yang
DOI: https://doi.org/10.1136/jitc-2020-000973
IF: 12.469
2020-10-01
Journal for ImmunoTherapy of Cancer
Abstract:Background Interleukin-2 (IL-2) serves as a pioneer of immunotherapeutic agent in cancer treatment. However, there is a considerable proportion of patients who cannot benefit from this therapy due to the limited clinical responses and dose-limiting toxicities. Mounting evidence indicates that commensal microbiota shapes the outcome of cancer immunotherapies. In this study, we aim to investigate the enhancing effect of Akkermansia muciniphila (AKK), a beneficial commensal microbe receiving considerable attentions, on the antitumor efficacy of IL-2 and explore the underlying molecular mechanism. Methods Colorectal carcinoma patient-derived tumor tissues were used to evaluate the therapeutic efficacy of combination treatment. AKK was orally delivered to B16F10 and CT26 tumor-bearing mice along with systemic IL-2 treatment. Flow cytometry was carried out to analyze the tumor immune microenvironment. The molecular mechanism of the enhanced therapeutic efficacy was explored by RNA-seq and then verified in tumor-bearing mice. Results Combined treatment with IL-2 and AKK showed a stronger antitumor efficacy in colorectal cancer patient-derived tumor tissues. Meanwhile, the therapeutic outcome of IL-2 was significantly potentiated by oral administration of AKK in subcutaneous melanoma and colorectal tumor-bearing mice, resulting from the strengthened antitumor immune surveillance. Mechanistically, the antitumor immune response elicited by AKK was partially mediated by Amuc, derived from the outer membrane protein of AKK, through activating toll-like receptor 2 (TLR2) signaling pathway. Besides, oral supplementation with AKK protected gut barrier function and maintained mucosal homeostasis under systemic IL-2 treatment. Conclusion These findings propose that IL-2 combined with AKK is a novel therapeutic strategy with prospecting application for cancer treatment in clinical practice.
oncology,immunology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: how to enhance the anti - tumor immune response and improve the tumor - clearing effect by combining IL - 2 immunotherapy with symbiotic probiotics (especially Akkermansia muciniphila, abbreviated as AKK). Specifically, the paper focuses on the following points: 1. **Limitations of IL - 2 treatment**: - IL - 2 is an important immunotherapeutic drug, but its clinical application is limited mainly due to limited efficacy and dose - related toxicity issues. Many patients do not respond well to IL - 2 treatment, and high - dose IL - 2 can cause serious side effects, such as vascular leak syndrome, pulmonary edema, etc. 2. **The role of the gut microbiota**: - There is increasing evidence that the gut microbiota plays an important role in the effectiveness of cancer immunotherapy. In particular, AKK, as a beneficial symbiotic microorganism, has been shown to improve the host's metabolic function and immune response, and is associated with a stronger anti - tumor immune response and better clinical outcomes. 3. **The potential of combination therapy**: - The research aims to explore whether AKK can overcome the limitations of IL - 2 monotherapy by enhancing the anti - tumor immune effect of IL - 2. In addition, the research also hopes to reveal the specific molecular mechanisms of AKK - mediated anti - tumor immune responses, as well as the role of AKK in maintaining gut barrier function and microbiota homeostasis. ### Main research content - **Experimental design**: - Use tumor tissues from colorectal cancer (CRC) patients and mouse models (B16F10 melanoma and CT26 colorectal cancer) for in vitro and in vivo experiments. - **Treatment methods**: - Treat with IL - 2 or AKK alone, and with the combination of the two. - **Evaluation indicators**: - Detect tumor cell apoptosis, changes in infiltrating lymphocytes in the tumor microenvironment, production of pro - inflammatory cytokines, gut barrier function, and microbiota homeostasis, etc. ### Results - **Enhanced anti - tumor effect**: - The combination therapy significantly enhanced the anti - tumor immune response, as manifested by a higher tumor cell apoptosis rate, more CD8+ T cells and fewer regulatory T cells (Tregs), while promoting the maturation of dendritic cells (DCs) and the activation of cytotoxic T lymphocytes (CTLs). - **Molecular mechanism**: - AKK activates the TLR2 signaling pathway through its outer membrane protein Amuc, thereby initiating the anti - tumor immune response. In addition, AKK helps protect gut barrier function and maintain gut microbiota homeostasis, reducing the gastrointestinal side effects caused by IL - 2 treatment. ### Conclusion This study shows that the combination therapy of IL - 2 and AKK is a promising new anti - cancer strategy that can enhance the anti - tumor immune response while reducing side effects, providing new ideas for future clinical applications. --- If you need to further understand the specific experimental methods or data analysis, please let me know, and I will continue to provide you with detailed explanations.